Cargando…

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

BACKGROUND: Nearly 0.5% of Iranians are infected with HCV. Peginterferon-alpha-2a and Peginterferon-alpha-2b are the two available types of interferon for the treatment of hepatitis C. Comparing the results of these two treatments is still a challenge. OBJECTIVES: The aim of this study was to compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pouresmaeeli, Mahdiyar, Alavian, Seyed Moayed, Keshvari, Maryam, Salimi, Shima, Mehrnoush, Leila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612773/ https://www.ncbi.nlm.nih.gov/pubmed/26504470 http://dx.doi.org/10.5812/hepatmon.30780

Ejemplares similares

The Comparative Efficacy and Safety of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV Infection: A Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2010)

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals
por: Sharafi, Heidar, et al.
Publicado: (2012)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study
por: El Raziky, Maissa, et al.
Publicado: (2013)

The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C
por: Kadjbaf, Danesh, et al.
Publicado: (2016)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran
por: Mehrazmay, Alireza, et al.
Publicado: (2013)

Interferon-alpha-2a/peginterferon: Various toxicities: 6 case reports
Publicado: (2022)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
por: Nakamura, Masato, et al.
Publicado: (2013)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

Interstitial pneumonia associated to peginterferon alpha-2a: A focus on lung function
por: Cortés-Telles, Arturo
Publicado: (2016)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C
por: Wang, Liang-Jen, et al.
Publicado: (2016)

Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment
por: Gozdas, Hasan Tahsin, et al.
Publicado: (2015)

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
por: Sharafi, Heidar, et al.
Publicado: (2012)

Efficacy of Peginterferon Alpha-2a vs. 2b for the Treatment of Chronic HCV: Interpretation of Results and Future Prospects
por: Khedmat, Hossein, et al.
Publicado: (2010)

Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis
por: Ying, Sang-Yu, et al.
Publicado: (2021)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Impact of the IL-10 Promoter Gene Polymorphisms in the Severity of Chronic Hepatitis B Infection
por: Ghaleh Baghi, Sahand, et al.
Publicado: (2015)

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
por: Behnava, Bita, et al.
Publicado: (2016)

Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study
por: Park, Sang Hoon, et al.
Publicado: (2012)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Concurrent acute interstitial pneumonia and pulmonary embolism during treatment with peginterferon alpha-2a and ribavirin in a patient with hepatitis C
por: Çoban, Hikmet, et al.
Publicado: (2014)

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials
por: Aminizadeh, Ehsan, et al.
Publicado: (2016)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
por: Powis, J, et al.
Publicado: (2008)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Peginterferon based therapy for chronic hepatitis C in the elderly patients
por: Bold, Adriana, et al.
Publicado: (2013)

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Hepatitis C-Related Cirrhosis with Sustained Prevention of Hepatocellular Carcinoma Recurrence by Long-Term Administration of Super-Low-Dose Peginterferon-Alpha 2b
por: Mamori, Satoshi, et al.
Publicado: (2011)

Plasma Zinc Level in Hepatitis C Patients With or Without Beta Thalassemia Major; Is There Any Difference?
por: Abbasinazari, Mohammad, et al.
Publicado: (2013)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
por: Yu, Jiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5gnmpnkd0co492l3kob6058k3a